Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Automatically detect candlestick patterns on any chart

Read How
Market News Market Pulse Stocks News ETF News Crypto News

Grace Therapeutics, Inc.

Contributing Author

Recent Articles by Grace Therapeutics, Inc.

Aug-13
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update GRCE GlobeNewswire
Aug-04
Grace Therapeutics Announces $10 Million Private Placement GRCE GlobeNewswire
Jul-28
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration GRCE GlobeNewswire
Jun-18
Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update GRCE +7.21% GlobeNewswire
Apr-23
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104 GRCE -45.48% GlobeNewswire
Apr-14
Grace Therapeutics Announces Abstract Highlighting STRIVE-ON Phase 3 Trial Results Accepted for Presentation at AAN 2026 GRCE +12.04% GlobeNewswire
Mar-19
Grace Therapeutics to Present Data on the Unmet Medical Needs and Potential Benefits of GTx-104 in the Treatment of aSAH at Upcoming Medical Conferences GRCE GlobeNewswire
Feb-25
Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference GRCE GlobeNewswire
Feb-12
Grace Therapeutics Announces Third Quarter 2026 Financial Results, Provides Business Update GRCE GlobeNewswire
Nov-17
Grace Therapeutics to Participate in 16th Annual Craig-Hallum Alpha Select Conference GRCE GlobeNewswire
Nov-13
Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update GRCE GlobeNewswire
Nov-11
Grace Therapeutics Announces Abstract Accepted for Presentation at Society of Vascular and Interventional Neurology Annual Meeting GRCE GlobeNewswire
Oct-23
Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review GRCE GlobeNewswire
Sep-22
Grace Therapeutics Pivotal Phase 3 STRIVE-ON Safety Trial Presented at 2025 Neurocritical Care Annual Meeting GRCE GlobeNewswire
Sep-18
Grace Therapeutics Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104 GRCE GlobeNewswire
Sep-04
Grace Therapeutics Announces Presentation at The H.C. Wainwright 27th Annual Global Investment Conference GRCE GlobeNewswire
Aug-27
Grace Therapeutics Announces U.S. Food and Drug Administration Acceptance for Review of New Drug Application for GTx-104 GRCE GlobeNewswire
Aug-12
Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update GRCE GlobeNewswire
Jun-25
Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104 GRCE GlobeNewswire
Jun-23
Grace Therapeutics Announces 2025 Fiscal Year-End Results, Provides Business Update GRCE GlobeNewswire
Jun-13
Grace Therapeutics to Participate in the 2025 BIO International Conference GRCE GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)